Specifications TableSubjectBiologySpecific subject areaBiochemistry, omics analysis, protein detectionType of dataTable, Text fileHow data were acquiredLiquid chromatography-tandem mass spectrometric analysis was carried out using Q Exactive high-resolution mass\
spectrometer (Thermo Fisher Scientific, USA) coupled with an Ultimate 3000 Nano-flow HPLC system (Thermo Fisher Scientific, USA)Data formatRaw, filteredParameters for data collection50 control samples blood serum from healthy volunteers and 49 samples from blood serum from patients with schizophreniaDescription of data collection- Digestion of proteins.\
- LC-MS/MS analysis.\
- Data processing.Data source locationMoscow, RussiaData accessibilityProteomic data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016297. <https://www.ebi.ac.uk/pride/archive/projects/PXD016297>**Value of the Data**•Dataset represents proteomes of serum samples from patients with schizophrenia as well as from control healthy volunteers, which can be compared to reveal molecular pathways of pathology.•Blood plasma serves as an attractive source of candidate protein markers and specific pathologies for molecular profiling, as it contains molecular components secreted by cells in diseased tissues, as well as factors involved in the development of pathophysiological processes.•Protein profiling are perspective to reveal for clinical monitoring of drug therapy, for identification of affected signalling pathways may indicate the direction of research for the development of a systematic approach to the diagnosis and classification of schizophrenia disease.•Protein profiles are available in the form of "∗.raw" and "∗.mgf" data that can be further processed by researchers using their own bioinformatics algorithms and analysed together with their own data.

1. Data description {#sec1}
===================

The dataset contains "∗.raw " and "∗.mgf " data obtained through the shotgun HPLC-MS/MS analysis of serum samples from 49 patients with schizophrenia and 50 healthy volunteers. Data are available via ProteomeXchange with identifier PXD016297 \[[@bib1]\]. Information about blood samples collected from patients with schizophrenia and control samples from healthy donors is presented in [Table 1](#tbl1){ref-type="table"}. Dataset covers 99 biological samples (see [Table 2](#tbl2){ref-type="table"}).Table 1Data of schizophrenia patients.Table 1ParameterPatients, n = 49Healthy volunteers, n = 50Male2619Female2331*Family status*Married615Divorced33Never married4032*Education*[a](#tbl1fna){ref-type="table-fn"}Incomplete secondary education21Secondary education815Secondary special education131Incomplete higher education74Higher education1929*Worker status*Student637Working813Unemployment100Disabled00*Average age, years*at the time of blood sampling27,0 ± 5,125,9 ± 5,8first appeal22,2--*Diagnostic tools to confirm schizophrenia* (Mann-Whitney *U* Test \< 0.05)Positive and Negative Syndrome Scale (PANSS)112,733,1The Bush-Francis Catatonia Rating Scale (BFCRS)8,00The 4-Item Negative Symptom Assessment (NSA-4)21,00[^1]Table 2Sample description.Table 2Sample IDFiles "∗.mgf ", "∗.raw "Size of "∗.mgf ", MBSize of "∗.raw ", MBType of setYGW735CNT_20190613_01_YGW73536,496299,933controlKOHYW0CNT_20190613_02_KOHYW032,508310,499controlF0TP43CNT_20190613_03_F0TP4312,141354,819controlSOV2XBCNT_20190613_04_SOV2XB55,592374,428controlUNRJB0CNT_20190613_05_UNRJB027,143309,493controlD06354CNT_20190613_06_D0635466,683375,034controlXTJKUACNT_20190613_07_XTJKUA20,075228,465controlBEZ9HTCNT_20190613_08_BEZ9HT62,221380,846controlJXR1JHCNT_20190613_09_JXR1JH71,333384,764controlV1KI56CNT_20190613_10_V1KI5665,864377,322control8EUMZSCNT_20190613_11_8EUMZS58,062369,257controlODFBCYCNT_20190613_12_ODFBCY55,578376,181controlCMIJXTKCNT_20190613_13_CMIJXTK61,93371,116control50DQE5CNT_20190613_14_50DQE571,957384,9controlA6KS1MCNT_20190613_15_A6KS1M30,391310,726controlADAAWOCNT_20190613_16_ADAAWO17,498183,466control0O78QXCNT_20190613_17_0O78QX59,479370,889control4GO4TMCNT_20190613_18_4GO4TM74,33386,428controlC5WJWQCNT_20190613_19_C5WJWQ31,879307,852controlFAGIC5CNT_20190613_20_FAGIC528,488275,702controlWML65YCNT_20190613_21_WML65Y84,281386,867control9L82ITCNT_20190613_22_9L82IT56,14369,903control6H1B6SCNT_20190613_23_6H1B6S20,307259,611controlHIH318CNT_20190613_24_HIH31827,607289,802control0SFACQCNT_20190613_25_0SFACQ20,354264,346control9U3UGDCNT_20190613_26_9U3UGD73,548376,671controlPZRMAKCNT_20190613_27_PZRMAK26,31310,059controlVLXKLOCNT_20190613_28_VLXKLO27,886309,922controlTANU6PCNT_20190613_29_TANU6P17,669244,21controlMUM0IXCNT_20190613_30_MUM0IX25,266328,986controlR6P2S2CNT_20190613_31_R6P2S277,756379,815controlKLSD4VCNT_20190613_32_KLSD4V61,32378,474control705M82CNT_20190613_33_705M8228,658312,383controlCLGU1QCNT_20190613_34_CLGU1Q61,026375,212controlZQRSP6CNT_20190613_35_ZQRSP627,541296,7control454ZZVCNT_20190613_36_454ZZV3,181242,924controlF40I59CNT_20190613_37_F40I5928,703292,511controlCAQSMOCNT_20190613_38_CAQSMO28,1287,196controlZM532 NCNT_20190613_39_ZM532 N51,479371,66control50O6VVCNT_20190613_40_50O6VV31,519311,755controlU9YFIRCNT_20190613_41_U9YFIR80,734371,034controlC47UZMCNT_20190613_42_C47UZM32,161316,571controlXJ6412CNT_20190613_43_XJ641234,698317,005control6ZKO63CNT_20190613_44_6ZKO6316,174190,94controlVMIHKLCNT_20190613_45_VMIHKL28,302285,948controlOQLRX4CNT_20190613_46_OQLRX431,157291,616controlNFP2WGCNT_20190613_47_NFP2WG85,756379,078control7CX0U3CNT_20190613_48_7CX0U365,229372,454controlHARVQQCNT_20190613_49_HARVQQ52,139373,033controlEX6CFHCNT_20190613_50_EX6CFH77,873370,668control  YC1350SCH_20190610_01_YC135068,356344,859schizophreniaCXB45FSCH_20190610_02_CXB45F30,051256,296schizophreniaZ354Y7SCH_20190610_03_Z354Y725,949272,672schizophreniaEFHMWBSCH_20190610_04_EFHMWB21,491272,698schizophreniaZW4912SCH_20190610_05_ZW491247,083372,386schizophreniaYM6648SCH_20190610_06_YM664836,862349,4schizophreniaXO4528SCH_20190610_07_XO452828,831309,772schizophrenia214009SCH_20190610_08_21400932,955329,272schizophreniaXT0224SCH_20190610_09_XT022426,24324,236schizophreniaXP2950SCH_20190610_10_XP295030,717322,526schizophreniaXZ8204SCH_20190610_11_XZ820428,852313,83schizophreniaZL4104SCH_20190610_12_ZL410430,721300,117schizophreniaQL4MJFSCH_20190610_13_QL4MJF9,633419,259schizophreniaTW2654SCH_20190610_14_TW265429,695319,599schizophreniaZM9268SCH_20190610_15_ZM926836,432331,841schizophrenia7T9E6NSCH_20190610_16_7T9E6N28,278306,671schizophrenia6BZGDCSCH_20190610_17_6BZGDC24,741294,882schizophreniaYN2166SCH_20190610_18_YN216639,257311,476schizophreniaWU2600SCH_20190610_19_WU260023,116280,623schizophreniaZE3674SCH_20190610_20_ZE367425,114361,736schizophreniaZT4320SCH_20190610_21_ZT432029,695297,123schizophreniaWZ0609SCH_20190610_22_WZ060926,424243,559schizophreniaXW7605rSCH_20190610_23_XW7605r27,021301,198schizophreniaTP9276SCH_20190610_24_TP927632,121282,769schizophreniaXS1165SCH_20190610_25_XS116526,678311,717schizophrenia7DLGDRSCH_20190610_26_7DLGDR40,358351,499schizophreniaZ3I4Y7SCH_20190610_27_Z3I4Y726,408288,453schizophreniaXP1143SCH_20190610_28_XP114327,226333,953schizophreniaXR1760SCH_20190610_29_XR176028,219306,195schizophreniaXW9999SCH_20190610_30_XW999930,625312,772schizophreniaYN7802SCH_20190610_31_YN780235,292300,74schizophreniaYM9980SCH_20190610_32_YM998033,33319,595schizophreniaXY2612SCH_20190610_33_XY261235,366332,174schizophrenia1B2AF3SCH_20190610_34_1B2AF331,84303,574schizophreniaKI2824SCH_20190610_35_KI282434,055308,374schizophreniaZ57012SCH_20190610_36_Z5701229,843353,113schizophreniaZ00291SCH_20190610_37_Z0029132,211342,074schizophreniaYX0920SCH_20190610_38_YX092032,216351,013schizophrenia2B2612SCH_20190610_39_2B261226,518273,173schizophreniaYN3925SCH_20190610_40_YN392525,788297,709schizophreniaGS4953SCH_20190610_41_GS495328,146314,648schizophreniaYT7896SCH_20190610_42_YT789627,905288,273schizophreniaZB6894SCH_20190610_43_ZB689432,331300,684schizophreniaXW6458SCH_20190610_44_XW645825,98312,08schizophreniaYS2187SCH_20190610_45_YS218737,132327,972schizophreniaZD0291SCH_20190610_46_ZD029143,1355,323schizophreniaXO6440SCH_20190610_47_XO644028,316292,074schizophreniaXX2845rSCH_20190610_48_XX2845r34,265350,4schizophrenia5O9UN9SCH_20190610_49_5O9UN927,288300,144schizophrenia

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Reagents {#sec2.1}
-------------

Acetonitrile and TCA were from Merck (Germany). Formic acid was from ACROS Organics (USA). Ethylenediaminetetraacetic acid (EDTA) was from Sigma-Aldrich (USA). Modified trypsin was from Promega (USA). MOPS (4-morphline-propane-sulphonic acid sodium salt), BUN, deoxycholic acid sodium salt, hydrogen carbonate of ammonium triethyl, ТСЕР (tris-(2-carboxyethil)-phosphine), 4-vinyl pyridine, propane-2 olefins, formic acid (Merck, Germany), deoxycholic acid, methanol, trifluoroacetic acid (Fluka, Germany).

2.2. BioSamples {#sec2.2}
---------------

These data include patients with a diagnosis of schizophrenia and healthy controls, all participants signed the informed consent form.

The group of patients: 49 patients (26 men, 23 women, average age 26.9 ± 5.2 years) who were hospitalized in State Healthcare Institution «Psychiatric Clinical Hospital 1 n. a. N.A. Alekseev of Healthcare Department of Moscow» from February to April 2019 with a diagnosis of schizophrenia.

The control group consisted of 50 volunteers from among employees, students and residents who have never sought psychiatric help and who are not related to patients.

2.3. Inclusion criteria {#sec2.3}
-----------------------

1.Age 18 or older2.Male or female3.Diagnosis of schizophrenia

The diagnosis of schizophrenia was established on the basis of the criteria of the International Classification of Diseases of the 10th revision (ICD-10) (see [Table 3](#tbl3){ref-type="table"}).Table 3Diagnosis data.Table 3The diagnosis of ICD-10F20.0F20.2F20.8F21.8F25.1F25.2The number of patients with an established diagnosis4132111

2.4. Non-inclusion criteria {#sec2.4}
---------------------------

1.Organic disease of the central nervous system;2.Decompensation of somatic disease;3.The period of pregnancy and lactation in women;4.Abuse of alcohol and psychoactive substances.

The clinical and psychometric methods used in the practice of research on mental pathology were used. A single examination of patients involves:-psychopathological and somatic examination;-psychometric examination using standardized international scales (PANSS, FAB, NSA-4, BFCRS)

Blood sampling (8--12 ml) was carried out in vacuum tubes with heparin in a treatment room in compliance with aseptic and antiseptic rules. Transportation to the laboratory was carried out within 2 hours from the moment of collection. Blood sampling was carried out once between 8 and 9 a.m. in the clinic\'s treatment rooms from a cubital vein into tubes with EDTA and a gel separator, followed by centrifugation of 2000 rpm for 20 minutes. The isolated serum was stored in eppendorf type microtubes at −80, whole blood was stored at −20 until transported to the laboratory. Transportation was carried out in compliance with material safety requirements.

2.5. Sample preparation for MS analysis {#sec2.5}
---------------------------------------

The blood plasma in the volume of 40 μl was then brought to the final volume of 160 μl by adding the solution 15 mM MOPS (4-morpholinepropanesulfonic acid sodium salt), рН 7.4.

The dry residue was restored in 500 μl of 0.1% deoxycholic acid sodium salt, 6% acetonitrile, 75 mM triethylammonium bicarbonate, рН 8.5. The protein solution was heated up at 90 °C for 10 minutes at intensive shaking (1100 rpm). After equilibration to ambient temperature, 3 mM ТСЕР (Tris (2-carboxyethyl)phosphine) was added to the denatured protein solution to restore the sulfhydryl groups of amino-acid residues of cysteine. The reaction was incubated at 45 °C for 20 minutes. For alkylation, the denatured protein solution was added with a solution of 0.2% 4-vinylpyridine in 30% propan-2-ol up to a final concentration of 0.02% (V/V). The alkylation reaction was carried out for 30 minutes at normal temperature in the lightproof place.

Enzymatic cleavage of proteins was performed using a specific trypsin protease. The protein solution was added with modified (acetylated at primary amino groups of lysine) trypsin at enzyme-to-substrate ratio as 1:50. The reaction was incubated at 42 °C for 4 hours with intermittent mixing for 3 minutes every 15 minutes. After that, the second aliquot of trypsin was added at ration 1:100 and incubated at 37 °C continued for additional 12 hours.

Upon the time expiry the enzyme reaction was inhibited by adding the formic acid up to the final concentration of 0.5%, which also caused precipitation of insoluble deoxycholic acid. The obtained suspended solids were centrifuged at 12,000 rpm at 15 °C for 10 minutes. The supernatant (approximately 550 μl) was collected and applied to Discovery DSC solid-phase columns, which were preliminary equilibrated with the solution of 2% methanol with 0.1% formic acid. After sample application the columns were washed twice with 1 ml of 0.1% formic acid solution, and then peptides were eluted from the carrier using the solution of 70% methanol with 5% formic acid in the volume of 1 ml. The collected Eliot was dried at 30 °C for 45 minutes in a vacuum. The dry residue was restored in 40 μl of 0.5% formic acid solution and transferred into vials of deactivated glass for mass spectrometry analysis \[[@bib2],[@bib3]\].

2.6. Mass spectrometry protein registration {#sec2.6}
-------------------------------------------

The mass spectrometric analysis of the peptide composition of plasma samples was conducted for depleted plasma samples. HPLC-MS/MS registration of peptides was carried out using high resolution mass spectrometer Q Exactive (Thermo Scientific, USA, Catalog \# IQLAAEGAAPFALGDK) by chromatographic separation using Ultimate 3000 Nano-flow HPLC system (Thermo Scientific, USA, Catalog \# ULTIM3000RSLCNANO). Peptides in the volume of 5 μl were applied on enrichment column PepMap C18 for 4 minutes in the isocratic flow of the mobile phase C (2% acetonitrile, 0.08% formic acid, 0.015% trifluoroacetic acid) at a flow rate of 20 μl/min. Peptides were separated using Acclaim PepMap C18 analytical column (75 mm × 150 μm, particle size 2 μm, pore size 100 A) in the nano-flow mode in the linear gradient of the mobile phase A (0.08% formic acid, 0.015% trifluoroacetic acid) and the mobile phase B (0.08% formic acid, 0.015% trifluoroacetic acid in acetonitrile) at a flow rate of s400 nl/min at initial ratio А: В as 98:2. Separation was performed in the elution gradient from 2% to 35% of mobile phase B content for 80 minutes, followed by column washing at 90% of phase B for 10 minutes with subsequent system equilibration at initial gradient conditions for 20 minutes.

Registration of peptide signal was carried out in the dependent tandem scan mode with ionization source NSI (Thermo Scientific, USA). After rescanning of precursor ions with maximum accumulation time not more than 80 ms (or maximum accumulation value 3е6) with resolution R = 70 K in the range of 420--1250 *m*/*z*, 20 sequential tandem scans were made with maximum accumulation time not more than 120 ms (or maximum accumulation value 1е5) with resolution R = 17.5 K a with fixed minimum range value (from 220 *m*/*z*) and varying maximum range value depending on the resolved charge state. Ions with charge state z = 2+ ... 5+ were selected for tandem scanning using the dynamic exclusion for the duration of one half-width of the chromatographic peak. Isolation of precursor ions was performed with the width of w = ±1 Th within the range from 9 to 17 s from the peak apex for the tandem scanning. Fragmentation was performed in the high-energy activation mode (HCD -- Higher-energy collisional dissociation) with rating 27% (per weight of 400 *m*/*z* and charge z = 2+) and variation per each scanning within ±15%. HPLC-MS/MS spectra in RAW format were processed in Mass Hunter version В 2.0 \[[@bib2],[@bib3]\].
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[^1]: Russia\'s Educational System.
